References
- Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim. Biophys. Acta 1812(8), 956–963 (2011).
- Zhou C, King N, Chen KY, Breslow JL. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J. Lipid Res. 50(10), 2004–2013 (2009).
- Howe K, Sanat F, Thumser AE, Coleman T, Plant N. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica. 41(7), 519–529 (2011).
- Swales KE, Moore R, Truss NJ et al. Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc. Res. 93(4), 674–681 (2012).
- Hagedorn KA, Cooke CL, Falck JR, Mitchell BF, Davidge ST. Regulation of vascular tone during pregnancy: a novel role for the pregnane X receptor. Hypertension 49(2), 328–333 (2007).
- Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 48(2), 373–384 (2007).
- Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl. Recept. Signal. 7e001 (2009).
- de Haan W, de Vries-van der Weij J, Mol IM et al. PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice. Biochim. Biophys. Acta 1791(3), 191–197 (2009).
- Hoekstra M, Lammers B, Out R, Li Z, Van Eck M, Van Berkel TJ. Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol. Pharm. 6(1), 182–189 (2009).
- Sui Y, Xu J, Rios-Pilier J, Zhou C. Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J. Lipid Res. 52(9), 1652–1659 (2011).
- Gao J, Xie W. Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab. Dispos. 38(12), 2091–2095 (2010).
- Hamlat N, Forcheron F, Negazzi S et al. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance. Cardiovasc. Diabetol. 8(1), 64 (2009).
- Glas J, Seiderer J, Fischer D et al. Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 17(9), 1917–1924 (2011).
- Hu G, Xu C, Staudinger JL. Pregnane X receptor is SUMOylated to repress the inflammatory response. J. Pharmacol. Exp. Ther. 335(2), 342–350 (2010).
- Wallace K, Cowie DE, Konstantinou DK et al. The PXR is a drug target for chronic inflammatory liver disease. J. Steroid Biochem. Mol. Biol. 120(2–3), 137–148 (2010).
- Cheng J, Shah YM, Ma X et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J. Pharmacol. Exp. Ther. 335(1), 32–41 (2010).
- Ghose R, Guo T, Vallejo JG, Gandhi A. Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. Drug Metab. Dispos. 39(5), 874–881 (2011).
- Ghose R, Omoluabi O, Gandhi A et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 89(1–2), 57–64 (2011).
- Aouabdi S, Gibson G, Plant N. Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor α binding site within the proximal promoter of PXR. Drug Metab. Dispos. 34(1), 138–144 (2006).